Dr Emer MacSweeney BSc (Hons), MRCP, FRCR and Founder & CEO Re:Cognition Health gives her view on the latest developments of treatments for Alzheimer’s.

Hugely important and game-changing success for new Alzheimer’s treatments has made headline news, globally, over the past few months.

In 2023 Leqembi was  approved by FDA (the USA drug regulatory board) for treatment of mild cognitive impairment (MCI) and early dementia, due to Alzheimer’s Disease (AD). Leqembi, a monoclonal antibody developed by Eisiai, removes toxic amyloid protein from the brain and slows progression of Alzheimer’s disease and its symptoms.

In July Eli Lilly announced the results of  the Trailblazer 2 study, for donanemab,  a medication with similar mechanism of action to leqembi. These results are very encouraging and certainly bring hope to people with Alzheimer’s disease, who urgently need new effective treatments.  Donanemab not only removed the toxic amyloid protein from the brain, but also slowed progression of early AD symptoms by 35% overall. Moreover, for those individuals with MCI, the rate of slowing of decline was 60%, with 50% of people showing no progression of symptoms after 1 year.

Re:Cognition Health has been undertaking clinical trials for these new medications, including leqembi; since 2013; indeed, all people in the UK currently on donanemab are in clinical trials at one of Re:Cognition Health’s six centres.

At The Alzheimer’s Dementia & Care Show – hear Dr Emer MacSweeney, talk about multiple new medications deigned to slow or ideally halt, and eventually prevent, the devastating symptoms of Alzheimer’s disease. Many of these medications are currently in clinical trial in the UK, and learn how you can have the chance, today, to change your, or a loved one’s, future.

For more information visit  www.re-cognitionhealth.com